- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 7, 2021
Distillery Therapeutics
A targeted CDK12 degrader for ALL
DISEASE CATEGORY: Cancer
INDICATION: Acute lymphoblastic leukemia (ALL) A CDK12-targeted degrader, designed by a Dana-Farber Cancer Institute and Harvard Medical School team co-led by Nathanael
INDICATION: Acute lymphoblastic leukemia (ALL) A CDK12-targeted degrader, designed by a Dana-Farber Cancer Institute and Harvard Medical School team co-led by Nathanael
Items per page:
1 - 5 of 5